Gary Rakes is a Rheumatology/Immunology physician. OpenAlex indexes 23 publications with 1,983 citations (h-index 12).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1415 Rolkin Ct
Suite 102
Charlottesville, VA 229113642
Telephone
434-951-2191Provider last certified this registry record 31 Oct 2023.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Regeneron Healthcare Solutions, Inc.Program year20251 payment
- Novartis Pharmaceuticals CorporationProgram year20241 payment
- Regeneron Healthcare Solutions, Inc.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
95.4%Corticosteroid42.3%Fluticasone Propionate31%Breo Ellipta26%Arnuity Ellipta23%Qvar Redihaler20%Part D<11 patientsCatecholamine16.5%Epinephrine100%Part D≥37 patients+ 3 more classes in this area
Dermatology
4.6%Corticosteroid4.6%Triamcinolone Acetonide100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 1999–2002 per NIH RePORTER. The latest:
- EXPERIMENTAL HUMAN RHINOVIRUS INFECTION IN PATIENTS W/ ASTHMA
University of Virginia Charlottesville
FY2002$48,533M01RR000847 - EXPERIMENTAL HUMAN RHINOVIRUS INFECTION IN PATIENTS W/ ASTHMA
University of Virginia Charlottesville
FY2001$48,533M01RR000847 - EXPERIMENTAL HUMAN RHINOVIRUS INFECTION IN PATIENTS W/ ASTHMA
University of Virginia Charlottesville
FY2000$28,104M01RR000847
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Assessment of Eosinophils, Viruses and IgE Antibody in Wheezing Infants and Children
International Archives of Allergy and Immunology
2009 - Improving Pediatric Asthma by the MSAGR Algorithm: A Multicolored, Simplified, Asthma Guideline Reminder
Pediatric Asthma Allergy & Immunology
2008 - A Pilot Study of Decision-Making Quality and Risk Behaviors in Rural Adolescents with Asthma
Pediatric Asthma Allergy & Immunology
2007 - Imaging the lungs in asthmatic patients by using hyperpolarized helium-3 magnetic resonance: Assessment of response to methacholine and exercise challenge
Journal of Allergy and Clinical Immunology
2003
Similar KOLs
Other experts from the same institution or the same specialty.
David J. Hunter
The University of Sydney
Aziz Sheikh
Universiti Malaysia Terengganu
Nima Hafezi‐Nejad
The University of Sydney
Gelin Xu
Second Affiliated Hospital of Nanjing Medical University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”